Home

Zynerba Earnings

Zynerba Pharmaceuticals last released its quarterly earnings results on May 12th, 2021. The reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.05. Zynerba Pharmaceuticals has generated ($1.90) earnings per share over the last year Zynerba Pharmaceuticals, Inc. (ZYNE) latest earnings report: revenue, EPS, surprise, history, news and analysis DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter. On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 20 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share Zynerba: Q1 Earnings Snapshot. DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter. On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 20 cents. The results exceeded Wall Street expectations

ZYNE Earnings Date, Forecast and Report (Zynerba

Zynerba: Q1 Earnings Snapshot. DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter. On a per-share basis, the Devon, Pennsylvania.. ZYNE Earnings. The latest earnings per stock, revenues and financial reports for Zynerba Pharmaceuticals Inc (ZYNE). We encourage you to use comments to engage with users, share your perspective. The company's earnings beat the Zacks Consensus Estimate in three of the last four quarters and missed the same once with the average surprise being 20.08%. Shares of Zynerba have declined 39.4% so..

Stay up to date with lastest Earnings Announcements for Zynerba Pharmaceuticals, Inc. from Zacks Investment Research ZYNE: Zynerba Pharmaceuticals, Inc. - Earnings News & Analysis - Zacks. Earnings ESP: Zynerba's Earnings ESP is 0.00%.This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 51 cents. You can uncover the best stocks to buy. Earnings Whispers. Our proven model does not conclusively predict an earnings beat for Zynerba in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below. You can uncover the best stocks to.

Zynerba Pharmaceuticals (NASDAQ: ZYNE) reported Q1 2021 earnings per share (EPS) of -$0.20, up 62.26% year over year. Total Zynerba Pharmaceuticals earnings for the quarter were -$7.96 million. In the same quarter last year, Zynerba Pharmaceuticals's earnings per share (EPS) was -$0.53 Zynerba: Q4 Earnings Snapshot The Devon, Pennsylvania-based company said it had a loss of 33 cents per share. The results topped Wall Street expectations. The average estimate of three analysts.. 10 Mar 21 Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights. Devon, PA, March 10, 2021 — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and.

Zynerba Delivers Earnings, Long Road Ahead For Zygel. Debra Borchardt March 10, 2021 15 min. 211. 0. Zynerba. Biotech company Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) reported its fourth-quarter and full-year results for the period ending in December. The company has no revenues to report at this time. The research and development expenses. Zynerba Pharmaceuticals, Inc. has a market cap of $193.89 Million and is expected to release its quarterly earnings report on November 09, 2020. With its Forward Dividend at 0 and a yield of 0%, the company's investors could be worried for the ZYNE stock to lose ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of -$0.2, with the EPS. Earnings History Data for Zynerba Pharmaceuticals, Inc. (ZYNE) - NYSE NASDAQ To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company Zynerba Pharmaceuticals 2016 Q4 - Results - Earnings Call Slides Mar. 27, 2017 Zynerba Pharmaceuticals (ZYNE) Presents At Oppenheimer 27th Annual Healthcare Conference - Slidesho Zynerba Pharmaceuticals, Inc. (ZYNE) projections and forecasts Looking at the company's year-over-year earnings, the past five years showed a positive earnings growth rate of 7.6%. Zynerba Pharmaceuticals, Inc. earnings are expected to decrease by -26.9% in 2021, but the outlook is negative 0% per year for the next five years

Zynerba: Q1 Earnings Snapshot. DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter. On a per-share basis, the Devon,.. Zynerba Pharma CS (ZYNE) Recent Earnings. Zynerba Pharma CS (ZYNE) reported a 1st Quarter March 2021 loss of $0.20 per share on revenue of $0.0 million. The consensus estimate was a loss of $0.24 per share. Earnings Whisper Zynerba Beats Estimates On Earnings. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) reported a net loss of $9 million for the third quarter ending September 30, 2020, with a basic and diluted net loss per share of $ (0.31). This beat the Yahoo Finance average analyst estimate for a loss of ($0.43)

Zynerba: Q1 Earnings Snapshot - 660 NEW

Zynerba Pharmaceuticals to Present at the 2019 Cantor

ZYNERBA: Q4 Earnings Snapshot: AQ. 03/10: ZYNERBA PHARMACEUTICALS : Reports Fourth Quarter and Full Year 2020 Financial R.. AQ. 03/04: ZYNERBA PHARMACEUTICALS : to Participate in the 33rd Annual ROTH Conference: AQ. 02/08: ZYNERBA PHARMACEUTICALS : Thinking about buying stock in Zomedica, Sundial Grow.. PR. More news: Financials (USD) Sales 2021---Net income 2021-42,4 M--Net cash 2021: 34,8 M. Zynerba: Q1 Earnings Snapshot. May 12, 2021 Updated: May 12, 2021 6:58 a.m. DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter.

Zynerba: Q1 Earnings Snapshot. May 12, 2021 Updated: May 12, 2021 5:58 a.m. DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter. Zynerba Pharmaceuticals Stock Earnings Report NASDAQ: ZYNE. Zynerba Pharmaceuticals Stock Earnings Report. Current P/E ratio: 0.0000 | Price (March 10, 2021, EOD): $4.34 (Find current average P/E ratios for all sectors below

Stocks Analysis by Zacks Investment Research covering: Gilead Sciences Inc, Horizon Pharma PLC, Corbus Pharmaceuticals Holding, Zynerba Pharmaceuticals Inc. Read Zacks Investment Research's latest. DEVON, Pa. _ Zynerba Pharmaceuticals Inc. on Monday reported a loss of $9 million in its third quarter. The Devon, Pennsylvania-based company said it had a loss of 31 cents per... | May 7, 202

DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $9.6 million in its fourth quarter. The Devon, Pennsylvania-based company said it had a loss of 33 cents.. ZYNE Zynerba Pharmaceuticals, Inc. Earnings Date History and Options Price Movements Analysi Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 4.06% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected 9.30% of gains in the last five trading sessions. Press Release reported on 06/11/21 that Zynerba Pharmaceuticals Present Zynerba Pharmaceuticals eps - earnings per share from 2014 to 2021. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants The latest earnings, revenues and financial reports for Zynerba Pharma (ZYNE)

Earnings ESP: Zynerba's Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 49 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: Zynerba currently carries a Zacks Rank #3 Earnings Whispers. Our proven model does not conclusively predict an earnings beat for Zynerba in this reporting cycle. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy. Zynerba Pharmaceuticals Inc. analyst estimates, including ZYNE earnings per share estimates and analyst recommendations Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Earnings History. Date EPS / Forecast Revenue / Forecast ; May 11, 2021. Equities analysts expect Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to post earnings of ($0.23) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Zynerba Pharmaceuticals' earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.22)

Zynerba: Q1 Earnings Snapshot - NEWS 113

  1. g in at ($0.27) and the highest estimate co
  2. Zynerba: Q1 Earnings Snapshot. DEVON, Pa. (AP) — Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter. On a per-share basis, the Devon.
  3. Zynerba Pharmaceuticals Inc. (ZYNE) EPS growth this year is -26.90%: Get Prepared for Trading Lift Off Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) open the trading on June 15, 2021, with a bit cautious approach as it glided -4.06% to $5.43. During the day, the stock rose to $5.67 and sunk to $5.36

Zynerba: Q1 Earnings Snapshot - 680 NEW

Earnings estimates and surprises for Zynerba Pharma CS (ZYNE) are an important tool used to evaluate the company's overall strength and value of the stock Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting. Read More. This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of $8 million in its first quarter. On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 20 cents. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was..

ZYNE Earnings Date & Report (Zynerba Pharmaceuticals Inc

On March 10, Zynerba reported its fourth-quarter earnings results. The company reported an EPS of -$0.33 in the fourth quarter compared to -$0.46 in the fourth quarter of 2019 Zynerba Pharmaceuticals, Inc financial statements, including revenue, expenses, profit, and loss The annual and quarterly earnings report below will help you understand the performance of ZYNE Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went up by 4.84% from its latest closing price compared to the recent 1-year high of $9.00. The company's stock price has collected -0.46% of loss in the last five trading sessions. Press Release reported on 04/06/21 that Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conferenc

Zynerba Pharmaceuticals Inc ZYNE:NASDAQ. Set Alert Options Streaming Charts. Last Price $5.07 NASDAQ Previous Close - Last Trade as of 3:59PM ET 6/01/21. Today's Change-0.61 (10.74%) Bid (Size) $5.13 (3) Ask (Size) $5.17 (3) Day Low / High $5.04 - 5.75. Volume 1.2 K. Sell. Buy. Snapshot; Charts; News; Options; Earnings; Fundamentals; Financials; Insiders; Actuals Estimates Surprises. Earnings. Zynerba Pharmaceuticals is the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra. The Investor Relations website contains information about Zynerba Pharmaceuticals Inc's business for stockholders, potential investors, and financial analysts

What's in the Cards for Zynerba (ZYNE) This Earnings

  1. Earnings ESP: Zynerba's Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 49 cents. You can uncover the best stocks to.
  2. Zynerba Pharma Earnings before Tax vs Revenue Per Employee relationship and correlation analysis over time
  3. Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric conditions. The firm offers Zygel product, which formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is.
  4. Zynerba Pharma Earnings Per Share vs. Price to Earning. Stocks USA. Stock Zynerba Pharma CS. Summary; Performance; Fundamentals; Technicals; Advice; Statements Indicators Trends Premiums Profitability Competition. ZYNE -- USA Stock : USD 4.65 0.05 1.06% : For Zynerba Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zynerba Pharma to.
  5. Zynerba Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.07% of US listed stocks. With a price/sales ratio of 1,661.62, Zynerba Pharmaceuticals Inc has a higher such ratio than 99.79% of stocks in our set. The volatility of Zynerba Pharmaceuticals Inc's share price is greater than that of 93.47% US stocks with at least 200.
  6. Zynerba: Q1 Earnings Snapshot. May 12, 2021 Updated: May 12, 2021 6:58 a.m. Facebook Twitter Email. Comments. DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Wednesday reported a loss of.
  7. DEVON, Pa. _ Zynerba Pharmaceuticals Inc. on Wednesday reported a loss of $8 million in its first quarter. On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 20... | May 12, 202

Zynerba Delivers Earnings, Long Road Ahead For Zygel. Biotech company Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) reported its fourth-quarter and full-year results for the period ending in December. The company has no revenues to report at this time. The research and development expenses were $5.6 million for the fourth quarter of 2020, including stock-based compensation of $0.6 million. Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the second quarter due to clinical studies on its lead pipeline candidate, Zygel Zynerba Pharmaceuticals (ZYNE) reported in-line with market expectation in the second quarter with earnings meeting estimates

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, has reported financial results for the first quarter ended March 31, 2021, and provided an overview of recent operational highlights and a pipeline update Earnings ESP: Zynerba's Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at a loss of 46 cents. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: Although Zynerba's Zacks Rank #2 increases the predictive power of ESP, its 0.00% ESP makes surprise prediction. For Zynerba Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zynerba Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zynerba Pharma CS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows. Zynerba stock forecast for 08.06.2021. Estimated Average Forecasted Zynerba Price: 5.80 Positive intraday dynamics of the instrument is expected with 4.423% volatility is expected. Pessimistic forecast: 5.70 Optimistic: 5.97 Zynerba stock forecast for 09.06.2021

Equities analysts expect Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) to post earnings of ($0.23) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Zynerba Pharmaceuticals' earnings, with the lowest EPS estimate coming in at ($0.24) and the highest estimate coming in at ($0.22) Zynerba Pharma Earnings Per Share is currently at (1.90) X. Earnings per Share (EPS) denotes the portion of Zynerba Pharma's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take Zynerba Pharma's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. We are committed to improving the.

Based on Zynerba Pharmaceuticals' latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.62 million. In comparison, last year the company had a GAAP net loss of $10.71 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks. Zynerba Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View ZYNE financial statements in full On a per-share basis, the Devon, Pennsylvania-based company said it had a loss of 47 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment. Zynerba Pharmaceuticals (ZYNE): Q1 GAAP EPS of -$0.20 beats by $0.05.Cash and cash equivalents of $93.1M as of March 31, 2021.Management believes that the Company's cash and cash equivalents as of March 31, 2021 are sufficient to fund operations and capital requirements well into the first half of 2024.Shares are down 1.20% PM.Press Release.. zynerba pharmaceuticals inc <zyne.o>::zynerba pharmaceuticals reports third quarter 2019 financial results and operational highlights.q3 loss per share $0.08.q3 earnings per share estimate $-0.52.

Zynerba Pharmaceuticals Announces the Acceptance of Two

Zynerba stock forecast for Dec 2024. Estimated Average Forecasted Zynerba Price: 9.25. Negative monthly dynamics of the instrument is expected with 14.953% volatility is expected. Pessimistic forecast: 8.62. Optimistic: 10.14. All currency forecasts. All stock predictions. All cryptocurrency predictions Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results. Aurora Cannabis Inc. (NYSE:ACB) (TSX:ACB) consolidated net revenue of CA$67.8 million ($52.3 million) for the first quarter of fiscal 2021, being up by around CA$300,000 from the fourth quarter of fisca... Other stocks mentioned: CGC, CNPOF. 7 months ago - Benzinga. Zynerba Pharmaceuticals Reports Third.

ZYNE: Zynerba Pharmaceuticals, Inc

Zynerba Pharmaceuticals Inc ZYNE Morningstar Rating Rating as of Jun 11, 2021. Quote Most Recent Earnings Mar 31, 2021. Fiscal Year End Dec 31, 2021. Stock Type Distressed. Employees 26. Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel

What's in the Cards for Zynerba (ZYNE) This Earnings Season

Zynerba completed enrollment in this trial in January 2020 and expects to report topline results in the second quarter of 2020 (Press release) New U.S. Patent Received for Treatment of ASD with. Q1 2021 Zynerba Pharmaceuticals Inc Earnings Release - Actual: -$0.20; 03/10/21 Q4 2020 Zynerba Pharmaceuticals Inc Earnings Release - Actual: -$0.33; 11/09/20 Q3 2020 Zynerba Pharmaceuticals Inc Earnings Release - Actual: -$0.31; 08/10/20 Q2 2020 Zynerba Pharmaceuticals Inc Earnings Release - Actual: -$0.78; More calendar event Earnings results for Zynerba Pharmaceuticals (NASDAQ:ZYNE) Zynerba Pharmaceuticals, Inc. is estimated to report earnings on 11/04/2020. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks. Zynerba's stock volume tops 600,000 shares premarket, already above full-day average of 590,000 Aug. 7, 2017 at 8:22 a.m. ET by Tomi Kilgore No Headlines Availabl

View the real-time ZYNE price chart on Robinhood and decide if you want to buy or sell commission-free. Change the date range, see whether others are buying or selling, read news, get earnings results, and compare Zynerba Pharmaceuticals against related stocks people have also bought like SPPI, AGEN, CPRX, and LLNW Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on research and development of rare and near-rare neuropsychiatric.

Stock analysis for Zynerba Pharmaceuticals Inc (ZYNE:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile Zynerba Pharmaceuticals Forecast Earnings Growth Zynerba According to present data Zynerba Pharmaceuticals's ZYNE shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). Currently there seems to be a trend where stocks in the Healthcare, Manufacturing sector(s) have been popular in this period. Our Ai stock analyst implies that there. What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks-8.47%. 06:50AM : Zynerba Pharmaceuticals Announces the Completion of Enrollment in the Pivotal CONNECT-FX Trial of Zygel in Fragile X Syndrome . GlobeNewswire. Feb-25-20 11:21AM : Zynerba Pharmaceuticals, Inc.'s (NASDAQ:ZYNE) Path To Profitability. Simply Wall St. +7.13%. 07:15AM : Zynerba Pharmaceuticals Receives New U.S.

Zynerba Pharmaceuticals Earnings & Revenue 2011-2021

Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. >Analyst Target Prices. The chart at the top shows a one-year chart for the symbol, with Earnings highlighted. Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. >Historical Rating Pot Stocks Earnings Calendar for June 2021. . All companies. ACB.TO - Aurora Cannabis. ACNNF - AusCann Group Holdings. ACRG-AU.CN - Acreage Holdings. AGRA.CN - AgraFlora Organics International. AH.TO - Aleafia Health. AHG.CN - Alternate Health Find real-time ZYNE - Zynerba Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business Zynerba Pharma Earnings before Tax vs Average Assets relationship and correlation analysis over time ZYNE News. Overall. ZYNE Stock Analysis Overview. What this means: InvestorsObserver gives Zynerba Pharma CS (ZYNE) an overall rank of 42, which is below average. Zynerba Pharma CS is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 42 means that 58% of stocks appear.

Zynerba: Q4 Earnings Snapshot - Yaho

  1. 7 Things To Know About Zynerba's Pipeline & Q2 Earnings Release. August 2, 2017. Zynerba Pharmaceutical's New Investor Presentation. June 26, 2017. Zynerba Reaches Target Enrollment in Phase 2 Fragile X Study. June 8, 2017. Marijuana Stocks with the Highest Trading Volume. June 1, 2017. Zynerba to Present at Jefferies Healthcare Conference . June 1, 2017. Insider Buying by CEO & CFO at Zynerba.
  2. Earnings Update: Aurora, Canopy Growth, Canopy Rivers And Zynerba Each Post Results Nina Zdinjak 11/9/2020. Jeff Bezos Fast Facts. A 'bloody crypto' Memorial Day weekend? Some bitcoin bulls.
  3. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) disclosed its first-quarter net loss of $8.0 million or a loss of 20 cents per share, compared to $12.34 million in the same period of 2020 or a loss.
  4. Zynerba Pharmaceuticals Reports Fourth Quarter and Full
Zynerba Pharmaceuticals Reports Fourth Quarter and YearRide the Cannabis Wave With These 3 Stocks4 Hot Analyst Reads For Friday, July 6th - Biotech NationBUZZ-U
  • McLaren Newport Beach.
  • Telekom Aktie Dividende.
  • Revolut Umtausch Limit.
  • Haus bauen in Norwegen Kosten.
  • CoinTracking Registrieren.
  • Quanteda.
  • Petzl Lynx.
  • CoinLoan Reddit.
  • Digipass DP772.
  • AirDisaster com accident database.
  • Investment AB Spiltan Avanza.
  • Allianz Riester Rechner.
  • Dividenden Aktien 2021.
  • Discord Sticker.
  • Alstom Produkte.
  • Mining frame Reddit.
  • Michel Perridon Foundation.
  • Deutsche Gold Aktien.
  • OBV indicator MT4.
  • Auto service finance.
  • Hilfe für Start up Unternehmen.
  • AirBuddy Mac download.
  • Apoteket glasögon närsynt.
  • E*TRADE Europe.
  • Narcos: Idle Cartel MOD APK.
  • Steam friends offline bug.
  • Compare fees crypto exchanges.
  • Ubuntu MATE support.
  • Coinbarn.
  • Delphi TObjectList.
  • BioNTech onvista Forum.
  • Online Casino Bonus ohne Einzahlung 2021.
  • BGF World Gold A2 EUR.
  • PDF editor Mac M1.
  • Buy PayPal balance.
  • Bellona Solven Yemek Odası.
  • Web3 get private key.
  • Interactive Brokers Marktdaten abonnieren.
  • Dreams Bed Cover.
  • Nano representatives.
  • Expedia.